SQZ Biotechnologies Co
sqzbiotech.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 8, 2023. Its latest SEC filing is a SC 13G/A from Feb 13, 2024.
10-Q for Q3 FY2023, filed Nov 8, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops engineered cell therapies that direct immune responses against cancer for patients with HPV-associated solid tumors and other serious conditions.
10-K for FY2022, filed Mar 22, 2023SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit…View ↗
In oncology, we are developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered…View ↗
Advance HPV-specific cell therapy for the treatment of HPV-associated solid tumor malignancies. We believe that HPV+ cancers represent a…View ↗
How Did They Make Money?
Partners may pay upfront license fees, research-cost reimbursements, option and development or regulatory milestones, and royalties on licensed-product sales; existing agreements have 60-day payment terms. Research-service payments are earned as services are provided, while a separate license fee is earned when the license transfers.
10-K for FY2022, filed Mar 22, 2023The Company enters into licensing arrangements that are within the scope of ASC 606, under which it may exclusively license to third…View ↗
F-11 performance obligation is distinct from the other promises, the Company considers factors such as the research, development…View ↗
Research and Development ServicesView ↗
$21.5M
-
10-K for FY2022, filed Mar 22, 2023
$21.5M ↗
Who Were Their Customers?
Third-party partners may license rights to research, develop, manufacture and commercialize product candidates; partners may also pay for research and development services.
Did Revenues Turn Into Profits?
No. It lost $79.5M in FY2022.
10-K for FY2022, filed Mar 22, 2023
−$80.7MView ↗
10-K for FY2022, filed Mar 22, 2023
−$79.5MView ↗
10-K for FY2022, filed Mar 22, 2023
−$84.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 8, 2023
−$23.6MView ↗
- ▲ +4% (Loss)
- vs −$22.6M in Q3 FY2022
-
Dec 22, 2023
Agreed to sell substantially all company assets
STEMCELL agreed to pay $11,800,000 in cash at closing; SQZ planned to wind down and prepare for dissolution.
Sources
8-K, filed Dec 22, 2023
On December 21, 2023, SQZ Biotechnologies Company (the “Company” or “SQZ”) entered into an Asset Purchase Agreement (the “Purchase…View ↗
-
Oct 2, 2023
Set Interim CEO’s employment termination
Transition agreements set termination dates for four executive officers, including Howard Bernstein, for November 15.
Sources
8-K, filed Oct 2, 2023
In connection with the Workforce Reduction, on October 3, 2023, the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive…View ↗
-
Sep 15, 2023
Ended Roche license and collaboration agreement
SQZ regained full clinical development and future commercialization rights for its oncology programs, including HPV16-positive tumors.
Sources
8-K, filed Sep 15, 2023
On September 13, 2023, SQZ Biotechnologies Company (the “Company” or “SQZ”), F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche…View ↗
-
Jul 3, 2023
NYSE began delisting proceedings
The company expected its stock to be delisted and said trading would move to over-the-counter markets.
Sources
8-K, filed Jul 3, 2023
On July 3, 2023, SQZ Biotechnologies Company (the “Company”) received a written notice from the New York Stock Exchange (“NYSE”) notifying…View ↗
Who Did They Compete With?
Competes with Fate Therapeutics, Kite, ISA Pharma, Cue Biopharma, BioNTech, Inovio, and Iovance Biotherapeutics
10-K for FY2022, filed Mar 22, 2023We expect to compete with companies using other cell engineering approaches, such as electroporation and viral vectors. Companies that are…View ↗
Loading...
